The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
The company’s stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
By Reuters
Share
Save
Save articles to read later and create your own reading list.
Healthcare giant Eli Lilly is now the first global healthcare company to hit $1 trillion in value riding on the popularity of…
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster…
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and…
